Dermatomycosis Market: Current Analysis and Forecast (2024-2032)
Emphasis on Drugs (Corticosteroids, Corticosteroid-sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, and Others); Route of Administration (Oral, Parenteral, Topical, and Others); End-User (Hospitals, Specialty Clinics, and Others); and Region/Country
Global Dermatomycosis Market Size & Forecast
The global dermatomycosis market was valued at ~USD 14 billion in 2023 and is expected to grow at a strong CAGR of around ~4% during the forecast period (2024-2032) owing to the increasing prevalence of fungal infections globally.
Global Dermatomycosis Market Analysis
The market size of Dermatomycosis across the globe is expanding because of several factors such as the increasing incidence of chronic diseases compromising immune systems, such as diabetes which will drive the growth of the market. Also advances in medical research and technology have led to the development of treatment options, which are gaining regulatory approvals and entering the market.
In November 2023, Basilea Pharmaceutica acquired rights to fosmanogepix, a broad-spectrum antifungal, through an agreement with Amplyx Pharmaceuticals. The transformative move strengthens Basilea’s clinical antifungal pipeline, with plans for phase 3 studies.
Global Dermatomycosis Market Trends
This section discusses the key market trends that are influencing the various segments of the global dermatomycosis market, as identified by our team of research experts.
Hospital Segment Transforming Industry
Hospitals play a critical role in driving the dermatomycosis market through their segmented approach to treatment, which includes specialized dermatology departments equipped to diagnose and manage fungal infections effectively. These facilities utilize a range of antifungal therapies, both topical and systemic, tailored to the severity and type of dermatomycosis. Hospitals also contribute significantly to market growth by serving as centers for clinical research, facilitating the development and adoption of innovative treatments. Moreover, their role in providing education to healthcare professionals and patients alike enhances awareness and improves treatment outcomes, thereby shaping the dermatomycosis market through comprehensive and specialized care delivery.
Asia-Pacific is Expected to Grow at a fastest CAGR During Forecast Period
The Asia Pacific dermatomycosis market is experiencing significant growth due to the rising prevalence of chronic diseases like diabetes, which increases susceptibility to fungal infections, and a growing awareness of personal hygiene and skincare. Rapid urbanization, changing lifestyles, and increased healthcare access in emerging economies such as China and India are driving demand for effective antifungal treatments. The region’s expanding middle class and increased healthcare spending further fuel market growth. Companies are increasingly investing in local manufacturing and distribution to cater to the diverse and large population. Moreover, partnerships with local healthcare providers and government initiatives aimed at improving healthcare infrastructure and disease management are crucial for market expansion in this region. The adoption of digital health technologies for remote diagnosis and treatment is also gaining traction, enhancing market reach and patient compliance.
Global Dermatomycosis Industry Overview
The global dermatomycosis market is competitive, with several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new type launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Pfizer Inc.; AstraZeneca; Eli Lilly and Company; GALDERMA LABORATORIES, L.P.; Hikma Pharmaceuticals PLC; Novartis AG; Johnson & Johnson Services, Inc.; Astellas Pharma US, Inc.; Mylan N.V.; Taro Pharmaceutical Industries Ltd.
Global Dermatomycosis Market Report Coverage
Reasons to buy this report:
- The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
- The report presents a quick review of overall industry performance at one glance.
- The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, type portfolios, expansion strategies, and recent developments.
- Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
- The study comprehensively covers the market across different segments.
- Deep dive regional level analysis of the industry.
Customization Options:
The global dermatomycosis market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to contact us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Global Dermatomycosis Market Analysis (2024-2032)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global dermatomycosis market were the three major steps undertaken to create and analyze the adoption of global dermatomycosis in major regions. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global Dermatomycosis market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the global Dermatomycosis market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the global dermatomycosis market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as drugs, route of administration, end-user, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the global dermatomycosis market. Further, we conducted factor analysis using dependent and independent variables such as drugs, route of administration, end-user, and regions of the global Dermatomycosis market. A thorough analysis was conducted of demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the global Dermatomycosis market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global Dermatomycosis market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to several factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
- The industry’s market size, in terms of revenue (USD) and the adoption rate of the global dermatomycosis market across the major markets domestically
- All percentage shares, splits, and breakdowns of market segments and sub-segments
- Key players in the Global Dermatomycosis market in terms of types offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global dermatomycosis market. Data was split into several segments and sub-segments after studying various parameters and trends in the drugs, route of administration, end-user, and regions in the global dermatomycosis market.
The main objective of the Global Dermatomycosis Market Study
The current & future market trends of the global dermatomycosis market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the market’s overall attractiveness at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
- Analyze the current and forecast market size of the global dermatomycosis market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments.
- Segments in the study include areas of the drugs, route of administration, end-user, and regions.
- Define and analyze the regulatory framework for the industry.
- Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
- Analyze the current and forecast market size of the global dermatomycosis market for the major regions.
- Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
- Company profiles of the global dermatomycosis market and the growth strategies the players adopt to sustain in the fast-growing market.
- Deep dive regional level analysis of the industry.
Frequently Asked Questions FAQs
Q1: What is the global dermatomycosis market’s current market size and growth potential?
Q2: What are the driving factors for the growth of the global dermatomycosis market?
Q3: Which segment has the largest share of the global dermatomycosis market by drugs category?
Q4: What are the emerging technologies and trends in the global dermatomycosis market?
Q5: Which region will dominate the global Dermatomycosis market?
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
